Skip to content
Open access

AAV-mediated Modulation of Dorsal Raphe Serotonergic Neurons Recapitulates Fenfluramine Efficacy in a Rat Model of Dravet Syndrome.

Oct 2026 · Molecular Therapy · 0 citations
Medicine

Abstract

Dravet Syndrome (DS) is a catastrophic developmental and epileptic encephalopathy (DEE) primarily caused by SCN1A haploinsufficiency. It is characterized by refractory hyperthermia-induced seizures, neurodevelopmental delay, and an elevated risk of sudden unexpected death in epilepsy (SUDEP) compared to other childhood epilepsies. While the small molecule fenfluramine (FFA) provides profound clinical benefit, its potential for systemic side effects and a poorly defined mechanism of action (MOA) underscores the need for more targeted interventions. Using a Scn1a+/- rat model of DS, we demonstrate that chronic FFA treatment reduces the frequency of hyperthermia-induced seizures and attenuates pathological EEG network hypersynchrony. Furthermore, FFA administration ameliorates hyperactivity and depressive-like comorbidities, an effect associated with a marked reduction in hippocampal neuroinflammation and microglial overactivation. Transcriptomic analysis implicated serotonergic signaling in the therapeutic response to FFA, and subsequent anatomical and functional analyses revealed enhanced activity of dorsal raphe nucleus (DRN) serotonergic neurons following FFA treatment. Cell-type-specific AAV-mediated modulation of DRN serotonergic neurons was sufficient to reproduce the key antiseizure and electrophysiological effects of FFA. Together, our findings identify the DRN serotonergic circuit as a therapeutically relevant circuit and provide proof-of-concept for mechanism-driven, circuit-specific neuromodulation strategies for Dravet syndrome.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.